Evidence Hub

Emerging Nonopioid Analgesic Strategies in Total Joint Arthroplasty: Mechanisms, Evidence, and Practical Implementation

Siddiqi A, Chen AF, Jacob P, Wickline A, Yousuf KM

The Journal of arthroplasty, 2026

4 citations

Abstract

BACKGROUND

Total joint arthroplasty (TJA), encompassing total hip and knee arthroplasty, remains one of the most effective procedures for end-stage arthritis, but is frequently associated with substantial postoperative pain. Opioid-based analgesia, although effective, carries risks of dependence, respiratory depression, and delayed recovery. In response to the opioid crisis, multimodal nonopioid strategies have gained prominence to improve outcomes while minimizing adverse effects.

METHODS

This review summarized current and emerging nonopioid analgesic modalities with clinical relevance to TJA. Recent randomized controlled trials, meta-analyses, and regulatory updates were analyzed to evaluate efficacy, safety, and practical integration into perioperative care.

RESULTS

Novel pharmacologic options-including suzetrigine (VX-548), a selective voltage-gated sodium 1.8 sodium channel blocker; intravenous meloxicam, a parenteral COX-2 inhibitor; and extended-release liposomal bupivacaine, demonstrate meaningful opioid-sparing effects with favorable tolerability profiles. Adjunctive nonpharmacologic modalities such as transcutaneous electrical nerve stimulation, sustained-acoustic-medicine ultrasound, and acupuncture offer complementary benefits by modulating peripheral and central sensitization. In addition, injectable hydrogel and polymer-based delivery systems represent a next generation of sustained local analgesia with the potential to extend pain control beyond 72 hours. The…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free